MX389883B - Formulacion basada en vitamina e o un ester de la misma para tratar biopeliculas bacterianas y fungicas - Google Patents

Formulacion basada en vitamina e o un ester de la misma para tratar biopeliculas bacterianas y fungicas

Info

Publication number
MX389883B
MX389883B MX2019013559A MX2019013559A MX389883B MX 389883 B MX389883 B MX 389883B MX 2019013559 A MX2019013559 A MX 2019013559A MX 2019013559 A MX2019013559 A MX 2019013559A MX 389883 B MX389883 B MX 389883B
Authority
MX
Mexico
Prior art keywords
ester
vitamin
treating bacterial
formulation based
fungal biofilms
Prior art date
Application number
MX2019013559A
Other languages
English (en)
Other versions
MX2019013559A (es
Inventor
Giorgio Panin
Original Assignee
Hulka S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hulka S R L filed Critical Hulka S R L
Publication of MX2019013559A publication Critical patent/MX2019013559A/es
Publication of MX389883B publication Critical patent/MX389883B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cosmetics (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Medicinal Preparation (AREA)

Abstract

La formulación para uso tópico basada en vitamina E o un éster de la misma para usarse en la remoción, reducción o inhibición de una biopelícula bacteriana y/o fúngica, donde el éster de vitamina E es un éster con un ácido carboxílico de fórmula R-COOH, en la cual R es un radical alquilo que tiene de 1 a 19 átomos de carbono o un alquenilo o alquinilo que tiene de 2 a 19 átomos de carbono.
MX2019013559A 2017-05-29 2018-05-28 Formulacion basada en vitamina e o un ester de la misma para tratar biopeliculas bacterianas y fungicas MX389883B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102017000058311A IT201700058311A1 (it) 2017-05-29 2017-05-29 Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini
PCT/EP2018/063926 WO2018219862A1 (en) 2017-05-29 2018-05-28 Formulation based on vitamin e or an ester thereof for treating bacterial and fungal biofilms

Publications (2)

Publication Number Publication Date
MX2019013559A MX2019013559A (es) 2022-02-03
MX389883B true MX389883B (es) 2025-03-20

Family

ID=60294053

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013559A MX389883B (es) 2017-05-29 2018-05-28 Formulacion basada en vitamina e o un ester de la misma para tratar biopeliculas bacterianas y fungicas

Country Status (24)

Country Link
US (3) US20200360339A1 (es)
EP (1) EP3630092B1 (es)
CN (1) CN110650737A (es)
AU (1) AU2018275487B2 (es)
BR (1) BR112019023962A8 (es)
CA (1) CA3061568C (es)
CL (1) CL2019003254A1 (es)
CY (1) CY1125414T1 (es)
DK (1) DK3630092T3 (es)
EA (1) EA201992190A1 (es)
ES (1) ES2919423T3 (es)
GE (2) GEP20207179B (es)
HR (1) HRP20220808T1 (es)
HU (1) HUE059185T2 (es)
IT (1) IT201700058311A1 (es)
LT (1) LT3630092T (es)
MA (1) MA48936B1 (es)
MX (1) MX389883B (es)
PL (1) PL3630092T3 (es)
PT (1) PT3630092T (es)
RS (1) RS63347B1 (es)
SI (1) SI3630092T1 (es)
SM (1) SMT202200274T1 (es)
WO (1) WO2018219862A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700058311A1 (it) * 2017-05-29 2018-11-29 Bio Lo Ga Srl Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini
WO2021228849A1 (en) * 2020-05-11 2021-11-18 Katholieke Universiteit Leuven Use of di- and tricarboxylic fatty acids in the prevention of biofilm formation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
JPH09169643A (ja) * 1995-12-22 1997-06-30 Sekisui Chem Co Ltd 寄生性皮膚疾患治療用外用剤
IT1302275B1 (it) * 1998-09-25 2000-09-05 Giorgio Panin Formulazione di gel idrofobo a base di vitamina e acetato perapplicazione topica.
EP2418945B1 (en) * 2009-04-15 2018-12-05 BMG PHARMA S.p.A. Mineral salt-sulfonic acid compositions and methods of use
ITUB20153889A1 (it) * 2015-09-25 2017-03-25 Bio Lo Ga Srl Gel idrofobico a base di vitamina E esente da prodotti siliconici per applicazione topica
ITUB20169882A1 (it) * 2016-01-08 2017-07-08 Flame S R L Vitamina E per l’uso nel trattamento e nella prevenzione delle infezioni da biofilm.
IT201700058311A1 (it) * 2017-05-29 2018-11-29 Bio Lo Ga Srl Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini

Also Published As

Publication number Publication date
GEAP201815201A (es) 2020-07-27
SMT202200274T1 (it) 2022-07-21
GEP20207179B (en) 2020-11-10
GEAP202015201A (en) 2020-07-27
DK3630092T3 (da) 2022-06-20
IT201700058311A1 (it) 2018-11-29
SI3630092T1 (sl) 2022-08-31
BR112019023962A8 (pt) 2022-07-05
EP3630092A1 (en) 2020-04-08
US20210228541A1 (en) 2021-07-29
MA48936A (fr) 2020-04-08
US20200360339A1 (en) 2020-11-19
AU2018275487B2 (en) 2024-03-14
HRP20220808T1 (hr) 2022-09-30
MA48936B1 (fr) 2022-08-31
US20200121638A1 (en) 2020-04-23
PL3630092T3 (pl) 2022-09-12
ES2919423T3 (es) 2022-07-26
WO2018219862A1 (en) 2018-12-06
CN110650737A (zh) 2020-01-03
HUE059185T2 (hu) 2022-10-28
EP3630092B1 (en) 2022-04-13
CA3061568C (en) 2024-02-13
RS63347B1 (sr) 2022-07-29
AU2018275487A1 (en) 2019-11-07
CA3061568A1 (en) 2018-12-06
MX2019013559A (es) 2022-02-03
CL2019003254A1 (es) 2020-07-03
EA201992190A1 (ru) 2020-09-03
LT3630092T (lt) 2022-06-27
CY1125414T1 (el) 2025-05-09
BR112019023962A2 (pt) 2020-06-09
US11234958B2 (en) 2022-02-01
PT3630092T (pt) 2022-06-02

Similar Documents

Publication Publication Date Title
MX2020012137A (es) Inhibidores de mcl-1.
BR112018015294A2 (pt) método e sistema para filetar um substrato metálico em uma unidade de laminação.
MX2019012535A (es) Combinacion que comprende un agonista de ppar tal como elafibranor y un inhibidor de la acetil-coa carboxilasa (acc).
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
CO2017006813A2 (es) Composiciones inhibidoras de corrosion para tratamientos acidificantes
CL2019003402A1 (es) Composiciones sólidas para administración oral.
AR098274A1 (es) Inhibidor de grelina o-acil transferasa
UY33885A (es) Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes
MX2020002823A (es) Fluorofenil beta-hidroxietilaminas y su uso en el tratamiento de la hiperglucemia.
AR102790A1 (es) Composiciones antimicrobianas y métodos relacionados para tratar productos alimenticios y superficies
MX2017015225A (es) Inhibidores de la autotaxina y sus usos.
GEAP201814046A (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
CO2017003969A2 (es) Derivado de isoxazol como inhibidor de isocitrato deshidrogenasa 1 mutante
AU2017247004A1 (en) Method of treating atherosclerosis
CL2016001192A1 (es) Uso de un inhibidor de dihidroorato deshidrogenasa (dhodh) para tratar enfermedades neurodegenerativas.
AR100407A1 (es) Aplicaciones volátiles contra patógenos
UY36574A (es) Inhibidores de bromodominios
CL2017002765A1 (es) El uso de estimuladores sgc, activadores gc, solos y combinaciones con inhibidores pde5 para el tratamiento de úlceras digitales (du) concomitante con esclerosis sistémica (ssc).
CY1122289T1 (el) Φαρμακευτικη συνθεση για χρηση στην αυξηση του τροφισμου της ρινικης βλεννογονου
CL2020000859A1 (es) Derivados de ácido glucónico para ser usados en el tratamiento y/o prevención de infecciones microbianas.
AR112217A1 (es) Una combinación de un inhibidor de mps1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
CL2019003254A1 (es) Formulación basada en vitamina e o un éster de la misma para tratar biopelículas bacterianas y fúngicas.
AR096597A1 (es) Composición refrigerante para motor de operación extendida
MX387859B (es) Una composición tópica basada en un derivado de niacinamida.